OncoMatch/Clinical Trials/NCT04877522
Asciminib Roll-over Study
Is NCT04877522 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments for chronic myelogenous leukemia.
Treatment: Asciminib single agent · Imatinib · Nilotinib · Bosutinib · Dasatinib · Asciminib single agent pediatric formulation — This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Myeloid Leukemia
Biomarker criteria
Required: BCR fusion
PH+ CML or PH+ ALL
Required: ABL1 fusion
PH+ CML or PH+ ALL
Prior therapy
Must have received: asciminib (asciminib) — currently receiving
currently receiving treatment with asciminib (single agent or in combination with imatinib, nilotinib or dasatinib)
Must have received: tyrosine kinase inhibitor (imatinib, nilotinib, bosutinib) — currently receiving
currently receiving treatment with ... imatinib, nilotinib or bosutinib alone
Cannot have received:
Participant has been discontinued from parent study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Michigan Med University of Michigan · Ann Arbor, Michigan
- Memorial Sloan Kettering · New York, New York
- Oregon Health Sciences University · Portland, Oregon
- Texas Oncology · Dallas, Texas
- Uni Of TX MD Anderson Cancer Cntr · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify